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LAY ABSTRACT
The aim of this study was to evaluate recurrence and 
early postoperative complications following surgical ex-
cision combined with radiotherapy for troublesome hip 
heterotopic ossification in patients with spinal cord injury 
and traumatic brain injury. Data from patients in BANK-
HO database with spinal cord injury or head injury who 
underwent surgical excision of hip heterotopic ossifica-
tion were included. Case patients underwent excision 
plus radiotherapy and controls only underwent excision. 
The primary end-point was recurrence. Secondary end-
points were postoperative complications and, more spe-
cifically, sepsis that required surgical revision. Data from 
19 case patients and 76 controls were analysed. There 
was no difference between groups regarding recurrence 
rate; however, the rate of sepsis requiring surgical revi-
sion was higher for patients who received radiotherapy. 
Based on the results of this study, we suggest that ra-
diotherapy should not be combined with surgery in pa-
tients with troublesome hip heterotopic ossification.
Objective: To evaluate recurrence and early post­
operative complications (sepsis) following surgical 
excision combined with radiotherapy for trouble­
some hip heterotopic ossification in patients with 
spinal cord injury and traumatic brain injury.
Design: Retrospective case­control study.
Setting: Data relating to patients with spinal cord 
injury or traumatic brain injury who underwent sur­
gical excision of hip heterotopic ossification were 
retrieved from the BANKHO database. Case patients 
underwent excision + radiotherapy, and controls un­
derwent excision only. Control patients were matched 
to case patients according to sex and age (± 4 years). 
Participants: Data from 19 case patients and 76 con­
trols were analysed. 
Main outcome measure: The primary end­point was 
recurrence of heterotopic ossification. Secondary end-
points were postoperative complications and, more 
specifically, sepsis that required surgical revision. 
Results: There was no difference between the odds 
ratios (OR) for recurrence for each group (OR case 
group = 0.63, OR spinal cord injury subgroup = 0.45 
and OR head injury subgroup = 1.04). The rate of 
sepsis requiring surgical revision was significantly 
higher in the case group (p < 0.05).
Conclusion: Based on the results of this case­control 
study, we suggest that radiotherapy should not be 
combined with surgery in patients with troublesome 
hip heterotopic ossification undergoing excision. Ra­
diotherapy does not appear to prevent recurrence 
and, moreover, it is associated with an increased 
risk of postoperative sepsis. 
Key words: heterotopic ossification; radiotherapy; recurren-
ce; spinal cord injury; traumatic brain injury; excision.
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Heterotopic ossification (HO) is defined as lamellar bone formation in non-osseous tissues (1, 2). It oc-
curs particularly in muscle and connective tissue, and is 
often triggered by a lesion to the central nervous system 
(CNS). There is currently no consensus regarding its 
management. Administration of non-steroidal anti-
inflammatory medication (NSAIDs) within the first 3 
weeks of the neurological lesion decreases the rate of 
occurrence of HO (3); however, their use is limited by 
potential adverse effects (4, 5). Bisphosphonates were 
once considered as a promising treatment, but are no 
longer used due to the risk of rebound effects following 
cessation (recurrence after discontinuation of drug 
therapy). Furthermore, they cannot be administered 
until ossification is in progress (6).
Surgical excision of HO is the current reference 
treatment (2, 7, 8). It is generally accepted that exci-
sion should be carried out as soon as the HO becomes 
troublesome, i.e., causes pain or reduces function (9). 
The main complication of excision is recurrence (7, 
10). Like the initial HO, the symptoms of recurrent HO 
may be sub-clinical (only seen on X-ray), may limit 
range of motion without affecting function, or may 
cause severe restrictions to function (10).
The rate of postoperative recurrence has rarely been 
evaluated, and a unanimous definition of recurrence 
is lacking in the literature (11–14). From the 1970s to 
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was diagnosed radiographically to be between 82% 
and 100%, but only 17–58% of HOs were associated 
with clinical signs (6, 10, 11, 15). In traumatic brain 
injury (TBI), recurrence was estimated to be 20% (16). 
Existing data suggests that the time between surgical 
excision and recurrence is the same as for initial HO 
after CNS injury: between 3 and 6 weeks (10), although 
it can be up to 3 months (17, 18). Contrary to previous 
beliefs, it has now been established that early surgery 
is not associated with recurrence of HO (9, 18–20). 
In a study of 357 patients (570 HO excisions), Genet 
et al. found no association between post-surgical 
recurrence and aetiology, sex, age or the presence of 
multisite HO. Furthermore, recurrence was not asso-
ciated with the time elapsed between the CNS lesion 
and surgery. None of the 181 patients studied, all of 
whom underwent surgery in the first year after their 
accident, experienced recurrence during follow-up (7). 
A systematic review that assessed combined treatments 
for HO to prevent recurrence in patients with SCI or 
TBI (21) could not draw any conclusion about the ef-
fectiveness of any treatments, since all of the studies 
were either case series or retrospective studies with 
small patient samples.
The prophylactic effect of radiotherapy on deve-
lopment of HO has been well-described following 
orthopaedic surgery (22–24), but its effect on HO 
in patients with neurological disorders is less well-
documented (2). It is believed that radiotherapy blocks 
mesenchymal stem cell differentiation into osteoblasts 
and bone precursor cells (11). Although radiotherapy 
is sometimes used, no studies have evaluated its ef-
fectiveness in patients with SCI and TBI to prevent 
recurrence of HO. 
Radiotherapy can be used either in the initial phase 
of development of HO (25–28) or to prevent recurren-
ces following surgical excision (26, 27, 29). Meiners et 
al. (30) evaluated the association of surgical excision 
and postoperative radiotherapy, and found a decrease in 
recurrence rate with radiotherapy. However, the study 
did not report the doses and techniques used, the indi-
cations for radiotherapy, or patient selection criteria. 
Several case reports (6 patients in total) have been 
published, in which radiotherapy was administrated as 
a first-line treatment for large HOs (25, 31, 32). The 
results showed a reduction in pain and an improvement 
in joint mobility for several months following the 
radiotherapy. Sautter-Bihl et al. evaluated the effects 
of radiotherapy on progression and recurrence in pa-
tients with SCI during the inflammatory phase of HO 
development and after surgical resection of the HO (26, 
27). They found that, in over 70% of the patients, HO 
development stopped following treatment. However, 
interpretation of the results is limited by the lack of 
homogeneity of the doses and fractionation protocols 
used. Finally, a retrospective case-control study repor-
ted that standard doses of radiotherapy did not reduce 
the recurrence rate (29).
The aims of this retrospective study were: (i) to assess 
whether radiotherapy associated with HO excision de-
creased post-excision recurrence of HO in patients with 
TBI and SCI and troublesome hip HO, and (ii) to eva-
luate the risk of associated post-operative complications.
MATERIAL AND METHODS
This was a single-centre, case-control study of data from the 
BANKHO database (Raymond Poincare hospital, Garches, 
France). This design was chosen based on published guidelines 
for epidemiological studies of this type (33), i.e. the retrospecti-
ve nature of the analysis and the small number of eligible records 
in the database from patients who had undergone radiotherapy. 
The BANKHO database contains all demographic, clinical and 
surgical data from patients who underwent surgical removal of 
HO following CNS injury since 1993 at our hospital. Indications 
for the surgical excision of HO were: (i) a loss of range of motion 
affecting function, (ii) pain or (iii) nervous or vascular compres-
sion. All surgeries and immediate postoperative evaluations 
were performed by the same orthopaedic surgeon. At the time 
of writing, 417 patients were listed in the database, including 
609 initial surgical resections of HO. The flow chart of patients 
included in the present study is shown in Fig. 1.
The inclusion criteria for the present study were: patients in 
the BANKHO database with TBI or SCI and who had undergone 
surgical excision of hip HO. 
The case patients had undergone HO excision, but, in addi-
tion, they had also received perioperative radiotherapy on the 
operated area. For the majority of case patients, the radiotherapy 
involved a single preoperative session, at a dose of 7.5 Gy, with 
15 or 18 MV X-ray photons (carried out the day before surgery). 
Each case patient (excision + radiotherapy) was paired with 4 
control patients (excision only). The controls were selected 
according to predefined matching criteria: aetiology (SCI or 
Fig. 1.  Study flow chart. HO: heterotopic ossification; RT: radiotherapy; 
SCI: spinal cord injury; TBI: traumatic brain injury.
Number of patients who 
underwent excision of 
HO 1995–2015  
506 
Number of patients 
who underwent 
excision + RT 
Number of patients 
who underwent 
excision without RT 
29 477 
Excluded patients 
total : 10 Cases Matched controls 
Aetiology other than 
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TBI), sex and age (±4 years). All the patients were operated on 
and followed-up in the same surgical department. All patients 
included were admitted between 1995 and 2015. Demographic 
and clinical data were collected for case and control patients. 
The primary outcome measure was recurrence of HO. 
Recurrence was defined as being troublesome, i.e. affecting 
sitting or gait due to pain or reduction in joint range of motion. 
Radiological recurrence, in the absence of clinical signs, was 
not considered. Secondary outcome measures were postopera-
tive complications of all types and complications that required 
revision due to sepsis.
Analysis of data in the BANKHO database was approved 
by the Committee for the Protection of Individuals. The study 
was non-interventional and routine procedures were used (i.e. 
no additional diagnostic procedures or medical supervision). 
Statistical analysis was carried out using Sigma Plot software 
version 12.5. The effect of radiotherapy on recurrence was 
tested using a χ2 test (or a Fisher’s exact test when necessary) 
and then by a multivariate logistic model. The variables used for 
matching (sex and age) were the dependent variables. Adjusted 
odds ratios (OR) were calculated with 95% confidence intervals 




A total of 29 patients in the BANKHO database under-
went perioperative radiotherapy. Of these, 10 did not 
fulfil the inclusion criteria (see flowchart; Fig. 1). The 
case group was composed of data from 19 male patients. 
These 19 patients were matched with 76 control patients, 
all of whom also underwent HO excision without ra-
diotherapy. Although the case and control groups were 
comparable with regard to certain characteristics (e.g. 
age at initial lesion, lesion level, ASIA score), there 
were also differences in the proportions of patients 
with multisite HO (case: 68.4% vs control: 35.5%), and 
recurrences after the first excision that required surgical 
revision (case: 78.9% vs control: 5.3%). 
Finally, the groups differed in terms of time from 
CNS lesion to first HO excision (12.6 vs 18 months). 
The difference in time from surgery to recurrence (19.3 
vs 51.7 months) could not be analysed due to the low 
number of recurrences in the control group (4 vs 15). 
Of the 95 patients whose data was analysed, 55 had SCI 
and 40 had TBI, and the recurrence rate was 14.7%. 
Of these, 29.5% had postoperative complications and 
22.1% needed surgery for the management of these 
complications.
Table I describes the demographic data for both 
groups (case and control).
Radiotherapy treatment details 
Only 21.1% of case patients received radiotherapy at 
the time of the first surgical excision. In the other pa-
tients of case group, radiotherapy was performed at the 
time of recurrence surgical excision. Most radiotherapy 
was performed preoperatively (89.5%), for logistical 
reasons. The protocol was one dose of 7.5 Gy in a 
single fraction (as recommended in the literature (34)). 
This was performed in 94.7% of cases. Detailed cha-
racteristics of the case group are presented in Table II.
Results for radiotherapy group (n=19)
Symptomatic recurrence occurred in 10.5% of the case 
patients (n = 2). Almost half of these patients (n = 9, 
47%) developed complications after surgical excision 
and radiotherapy, requiring surgical revision. It was 
always due to postoperative sepsis. Revision was car-
ried out at a median of 28 days following excision. The 
mean follow-up time for this group was 11.7 months.
Results for control group (n=76)
Symptomatic recurrence occurred in 5.3 % of the con-
trol patients (n = 4). Almost one-third of these patients 
(n = 23.3%) developed complications after surgical 
excision and 21% (n = 16) required surgical revision, 
due to postoperative sepsis. Revision was carried out 
Table I. Patients’ characteristics
 Case group (n = 19) (%) Control group (n = 76) 
Sex ratio, n (%) 19 males (100) 76 males (100)
Aetiology: spinal cord injury/traumatic brain injury, n (%) 11 (57.9)/8 (42.1) 44 (57.9)/32 (42.1)
Level of spinal cord injury, n (%)
Cervical 3 (27.3) 11 (25)
Thoracic 8 (72.7 ) 30 (68.2)
Lumbar 0 2 (4.5)
Complete spinal cord injury: ASIA score = A, n (%) 9 (81.8) 32 (72.7)
Age at central nervous system lesion, years, median (Q1–Q3) 24.2 (21.7–31.2) 25.3 (20.3–31.7)
Multisite heterotopic ossification, n (%) 13 (68.4) 27 (35.5)
Time from central nervous system lesion to surgery in months, median (Q1–Q3) 12.6 (10–19.8) 18 (11.7–48.4)
Table II. Detailed characteristics of the case group
 Case group (n = 19)
Age at time of radiotherapy, years, median (Q1–Q3) 32.3 (24.8–36.8)
Timing of radiotherapy relative to excision, n (%)  
Pre-operative 17 (89.5)
Post-operative 2 (10.5)
Radiotherapy dose: 7.5 Gy/12 Gy, n (%) 18 (94.7)/1 (5.3)
Fractionated radiotherapy (number of doses): 1/3, n (%) 18 (94.7)/1 (5.3)
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at a median of 27 days following excision. The mean 
follow-up time for this group was 25 months.
The results of the 2 groups are presented in Table III. 
Univariate analysis 
Univariate analysis revealed no significant relationship 
between radiotherapy and recurrence of HO (odds ratio 
(OR) 0.63, 95% CI: 0.06–3, 27; p = 0.72). Equally, 
no correlation was found between radiotherapy and 
postoperative complications (all complications pooled) 
(OR 2.7, p = 0.056). However, there was a significant 
correlation between radiotherapy and sepsis that requi-
red surgical revision (OR 4.70, 95% CI: 1.38–16.26, 
p < 0.05). In the TBI subgroup, this relationship was not 
significant (OR 4.00, p = 0.13, 95% CI: 0.45–33.39) but 
it was significant in the SCI subgroup (OR 5.19, 95% 
CI: 1.04–27.90, p < 0.05). The results of the univariate 
analysis, for the primary and secondary outcome mea-
sures, for the total population (SCI + TBI) as well as 
the subgroups, are presented in Table IV.
Multiple logistic regressions for the primary 
outcome measure
There was no significant relationship between radio-
therapy and incidence of recurrence, even when the 
matching variables (age and sex) and subgroups (TBI 




This study did not find any relationship between ra-
diotherapy administered at the time of HO excision and 
recurrence in patients with CNS disorders. Moreover, 
postoperative complications occurred more frequently 
in patients who underwent radiotherapy, particularly 
those with SCI.
Radiotherapy and HO
These data concurred with a previous case-control 
study by Cipriano et al. (29), which did not support the 
use of radiotherapy for the prevention of HO recurrence 
after excision in patients at risk of recurrence. Howe-
ver, a recent retrospective study suggested some effec-
tiveness of radiotherapy to treat HO (28). Patients with 
SCI underwent twice-weekly ultrasounds to screen for 
HO, followed by magnetic resonance imaging (MRI) 
or computed tomography (CT) scans if HO was suspec-
ted. If diagnosed, a single dose of radiotherapy (7 Gy) 
was administered. Only 5.3% of the patients treated 
with radiotherapy experienced progression (presence 
of clinical signs) of HO, requiring further radiotherapy; 
however, the mean follow-up time was only 89.4 days 
(standard deviation (SD) 76 days) after the initial 
radiotherapy. Moreover, the spontaneous progress of 
HO is currently unknown (i.e. it is unclear how many 
HO cases would have remained sub-clinical and how 
many would have gone on to become “troublesome”). 
In the future, one of the main challenges for the 
management of HO will be to understand the pathophy-
siology of its development. An important question is to 
determine whether HO seen on imaging will be likely 
to go on to become symptomatic and troublesome. One 
problem when reviewing literature on the prevalence 
Table III. Results for radiotherapy and control groups
 Case group (n = 19) Control group (n = 76)
Radiotherapy after 1st excision, n (%) 4 (21.1) 0 (0)
Recurrence after 1st excision, n (%) 15 (78.9) 12 (15.8)
Recurrence after 1st excision requiring surgical revision, n (%) 15 (78.9) 4 (5.3)
Symptomatic recurrence after excision+ radiotherapy, n (%) 2 (10.5)
Time from excision to recurrence, months, median (Q1–Q3) 19.3 (16.2–68.1) 51.7 (7.0–115.2)
Postoperative complications, all causes, n (%) 9 (47.4) 23 (30.3)
Postoperative sepsis requiring revision, n (%) 9 (47.4) 16 (21.1)
Time from excision to revision for complication, days, median (Q1–Q3) 28 (23–36) 27 (15–156)
Follow-up, months, median (Q1–Q3) 11.7 (5.2–29.8) 25 (4.25–87)
Table IV. Results of the univariate analysis for the primary and 
secondary outcomes 
 OR Statistical test p-value 95% CI
Primary outcome: recurrence
Total population 0.63 Fisher’s exact 0.72 0.06–3.27
Spinal cord injury 0.46 Fisher’s exact 0.67 0.01–4.16
Traumatic brain injury 1 Fisher’s exact 1 0.02–12.51
Secondary outcomes: all postoperative complications
Total population 2.7 χ2 0.056  
Spinal cord injury 2.8 Fisher’s exact 0.16 0.59–13.94
Traumatic brain injury 2.5 Fisher’s exact 0.35 0.31–18.00
Secondary outcomes: sepsis requiring surgical revision
Total population 4.7 Fisher’s exact 0.005 1.38–16.26
Spinal cord injury 5.19 Fisher’s exact 0.0022 1.04–27.90
Traumatic brain injury 4 Fisher’s exact 0.13 0.45–33.39 
SCI: spinal cord injury, OR: odds ratio, TBI: traumatic brain injury.
Table V. Results of the multiple logistic regression on the main 
outcome (recurrence) 
Odds ratio 95% CI
Total population 0.631 0.180–3.116
Spinal cord injury 0.449 0.050–4.063
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of HO is the heterogeneity of sample characteristics in 
the publications. In studies of surgical intervention, HO 
tends to be troublesome, and thus excision is indicated. 
In medical studies, however, HO is often discovered 
by imaging (systematic screening by ultrasound) and 
confirmed by either CT or MRI scans (28, 35)) without 
having been first described as troublesome.
Infectious complications
The results of the present study suggest that prophy-
laxis by radiotherapy is more effective for patients 
with SCI than for those with TBI. However, the risk of 
sepsis (a postoperative complication requiring surgical 
revision) is elevated for patients with SCI. Patients 
with SCI are generally at a higher risk of infection 
due to pressure sores, chronic bacteriaemia, immu-
nosuppression, etc. There is little data in the literature 
regarding acute, radiotherapy-related complications 
in SCI. In one study of patients who underwent total 
hip arthroplasty, with radiotherapy administered pre- 
or post-operatively to prevent HO, reoperation was 
required in 9% (removal of painful haematomas and 
explanation of an infected prosthesis). There was no 
difference in rate of reoperation between those who 
underwent pre- or post-operative radiotherapy (36). 
However, this data cannot be extrapolated to patients 
with CNS lesions. 
Gatin et al. (37) recently demonstrated that a higher 
American Society of Anesthesiologists (ASA) score, 
younger age, and spinal cord injury as the cause of HO 
at the hip are risk factors for post-operative infection 
(POI). The proportion of patients with POI after hip HO 
excision was 10%, in accordance with previous reports.
Oncological risk 
Radiotherapy is associated with an increased risk of 
cancer, although according to the literature, the risk 
is very low (38–40), particularly following a single 
radiotherapy session at a dose of less than 30 Gy (41). 
The follow-up duration in this study was not long 
enough to assess this risk; however, precautions were 
taken, as recommended by Seegenschmiedt et al., to 
protect the organs with the highest risk (bladder, rectum 
and colon) using lead shields (42). 
Study limitations
The lack of significance regarding the effect of ra-
diotherapy for the prevention of HO could be due 
to recruitment bias or a lack of statistical power. It 
is reasonable to assume that selection bias occurred, 
since the patients who underwent radiotherapy had 
the characteristics of patients in whom HO typically 
recurs: post-excision recurrence had occurred in 78.9% 
of the patients who received radiotherapy compared 
with only 5.3% of the patients in the control group. 
Multisite HO was also more common in the case gro-
up than the control group (69% vs 36%) although this 
is not a currently recognized recurrence risk factor (7). 
Time from CNS lesion onset to initial surgery also dif-
fered between groups, although this is also not known 
to be associated with an increased risk of recurrence 
(16, 18). These differences could be attributed to the 
fact that surgery was a higher priority in the case group 
because of the presence of multi-site HO. Patients most 
at risk of recurrence were selected upstream based on 
empirically recognized risk factors (neurogenic bladder 
and pressure sores for patients with SCI, autonomic 
dysfunction in patients with TBI and SCI), or because 
they had already experienced post-surgical recurrence. 
Because this was a retrospective study, there was no 
blinding, and patients with a higher risk of recurrence 
were prescribed radiotherapy, similarly to the study by 
Cipriano et al. (29).
Another possible limitation is the long inclusion pe-
riod, from 1995 and 2015. During this period, a single 
surgeon performed all HO excisions; however, the prop-
hylactic antibiotic regimen was changed in May 2007 
due to the high rate of POI (10%). No differences in POI 
frequency were found in the current study for surgery car-
ried out before and after the change in antibiotic regimen.
Conclusion
Based on the results of this small case-control study, 
we would not recommend radiotherapy to prevent 
recurrence of HO in patients with troublesome hip 
HO, requiring surgical excision who are at high risk 
of recurrence. Not only does radiotherapy appear to 
be ineffective in preventing recurrence, but it is also 
associated with an increase in postoperative compli-
cations, particularly sepsis.
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